A three-group meta-analysis showed that immunotherapy affected periodontal disease progression by modulating local immune factors IL-1β, IL-17, IL-6, IL-8 and TNF-α, thus providing a potential statistically significant benefit. Here, IL17A is linked to periodontal disorder.